Euretos AI platform - cloud access
The Euretos AI platform is the premier data driven platform for disease and drug research. It provides novel insights through unique Search, Analytics, Relation Map Analysis and Target Assessment & Discovery applications that leverage the world’s largest AI integrated knowledge base.
World's largest AI-integrated knowledge base
We use AI to connect over 275 life sciences databases and millions of publications and patents. This gives you access to the largest AI-harmonized knowledge base for molecular disease and drug research.
Intelligent and proactive Search
Our AI driven search engine automatically includes all synonyms of your search terms and finds database entries that Google can’t display. It gives you a list of all related terms to your query in 100+ categories, ranked on number of references. It interprets your queries and provides suggestions for what to explore next. Search also includes the following workflows:
- Target Review (functional role of a target)
- Gene-Disease Analysis
- Set Creation
Powerful and intuitive Analytics
Euretos Analytics evaluates your experimental data against the entire knowledge base. It combines sets to create informative set overlays. These sets can either be uploaded by you or created using Search. It analyzes and ranks these overlays giving you new insights into underlying common factors, differentiators and associations. Analytics also includes the following workflows:
- Gene Set Enrichment
- Gene Set Ranking
- Transcription Network Analysis
Visualized, low-bias Relation Maps
The Relation Map visualizes relations from databases, such as molecular interactions, expression values and human annotations. These visual maps enable unique, low-bias insights such as term clustering, indirect associations and term centrality. This way you can test your hypothesis, create your own disease models and share these as powerful visualizations.
Target Discovery in cancer
We have created powerful workflows to discover targets in oncology for compounds, antibodies and bispecific antibodies. These enable you to discover targets with high tumor expression and low expression in normal tissues to find selective, tumor specific targets. Two workflows are offered:
- Target Discovery for Cancer
- Target Discovery for Bispecific Antibodies.